TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05061550: A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Sponsor: AstraZeneca · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 630 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$12,705,000

Rescue Site Savings

+$8,408,400

Unlock Full NCT05061550 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05061550 Rescue Dossier →